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Background: Percutaneous recanalization of total coronary occlusion (TCO) was historically hampered by high rates
of restenosis and reocclusions. The PRISON II trial demonstrated a significant restenosis reduction in patients treated
with sirolimus-eluting stents compared with bare metal stents for TCO. Similar reductions in restenosis were
observed with the second-generation zotarolimus-eluting stent and everolimus-eluting stent. Despite favorable
anti-restenotic efficacy, safety concerns evolved after identifying an increased rate of very late stent thrombosis
(VLST) with drug-eluting stents (DES) for the treatment of TCO. Late malapposition caused by hypersensitivity
reactions and chronic inflammation was suggested as a probable cause of these VLST. New DES with bioresorbable
polymer coatings were developed to address these safety concerns. No randomized trials have evaluated the
efficacy and safety of the new-generation DES with bioresorbable polymers in patients treated for TCO.
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Methods/Design: The prospective, randomized, single-blinded, multicenter, non-inferiority PRISON IV trial was
designed to evaluate the safety, efficacy, and angiographic outcome of hybrid sirolimus-eluting stents with
bioresorbable polymers (Orsiro; Biotronik, Berlin, Germany) compared with everolimus-eluting stents with durable
polymers (Xience Prime/Xpedition; Abbott Vascular, Santa Clara, CA, USA) in patients with successfully recanalized
TCOs. In total, 330 patients have been randomly allocated to each treatment arm. Patients are eligible with
estimated duration of TCO ≥4 weeks with evidence of ischemia in the supply area of the TCO. The primary
endpoint is in-segment late luminal loss at 9-month follow-up angiography. Secondary angiographic endpoints
include in-stent late luminal loss, minimal luminal diameter, percentage of diameter stenosis, in-stent and
in-segment binary restenosis and reocclusions at 9-month follow-up. Additionally, optical coherence tomography is
performed in the first 60 randomized patients at 9 months to assess neointima thickness, percentage of neointima
coverage, and stent strut malapposition and coverage. Personnel blinded to the allocated treatment will review all
angiographic and optical coherence assessments. Secondary clinical endpoints include major adverse cardiac
events, clinically driven target vessel revascularization, target vessel failure and stent thrombosis to 5-year clinical
follow-up. An independent clinical event committee blinded to the allocated treatment will review all clinical
events.
Trial registration: Clinical Trials.gov: NCT01516723. Patient recruitment started in February 2012.
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Percutaneous coronary intervention (PCI) of total coron-
ary occlusion (TCO) was limited by high rates of resten-
osis in patients treated with bare metal stents or plain
old balloon angioplasty [1-4]. The introduction of drug-
eluting stents (DES) demonstrated a significant reduc-
tion in restenosis and reocclusions [5,6]. The Primary
Stenting of Occluded Native Coronary Arteries
(PRISON) II trial was the first randomized trial in
patients treated for TCOs that demonstrated a signifi-
cant reduction in restenosis and reocclusions with
sirolimus-eluting stents (SES) (Cypher; Cordis Corpor-
ation, Bridgewater, NY, USA) compared with bare metal
stents [7]. The rate of in-segment binary restenosis was
reduced from 41% to 11% in favor of SES. Clinical out-
come remained significantly in favor of SES for up to 5
years, despite a higher rate of late and very late stent
thrombosis (VLST) [8,9]. Second-generation DES were
developed to address safety concerns for VLST observed
in lesions treated with SES and paclitaxel-eluting stents
[10-13].
In the PRISON III trial we compared two zotarolimus-
eluting stents (ZES), the Endeavor ZES and the Resolute
ZES (both Medtronic Inc., Minneapolis, MN, USA), with
SES in patients treated for TCO [14]. Results after 1 year
demonstrated similar efficacy and safety of the Resolute
ZES compared with SES. However, the lesions treated
with the Endeavor ZES showed a higher rate of late lu-
minal loss, and a trend towards an increased rate of tar-
get lesion revascularization compared with SES.
Furthermore, no stent thrombosis was observed in the
Endeavor ZES or Resolute ZES groups, and only one
possible stent thrombosis after SES implantation. Longerfollow-up of this cohort is needed to observe the occur-
rence of VLST.
The everolimus-eluting stents (EES; Xience V/Xience
Prime; Abbott Vascular, Santa Clara, CA, USA), also
second-generation DES, showed a low rate of late lu-
minal loss in the treatment of nonobstructive lesions
with favorable clinical outcome [15]. The first results of
EES in chronic total occlusions are encouraging and the
CIBELES trial, which compares EES with SES in chronic
total occlusions, is currently ongoing [16,17].
Despite the promising results of second-generation
DES, new concerns have been raised after identifying
hypersensitivity reactions caused by the durable polymer
coatings of DES [18,19]. These reactions lead to chronic
inflammation and possible late stent strut malapposition,
which may lead to the development of VLST and
delayed restenosis [20]. To address these limitations,
new DES with bioresorbable polymer coatings have been
developed. These polymers degrade gradually over the
course of several months, resulting in controlled drug
release without leaving inflammatory stimuli. A proof of
concept for this new technology was recently demon-
strated in the LEADERS trial [21]. The study was not
powered for VLST. However, the group treated with
biolimus-eluting stents with bioresorbable polymers
showed a reduction of VLST by 80% relative risk at 4
years compared with conventional SES. Recently, a new
hybrid sirolimus-eluting stent (Orsiro; Biotronik SE &
Co. KG, Berlin, Germany) with bioresorbable polymers
was developed. The first human study (BIOFLOW-I;
Clinical Trial.gov: NCT01214148) in patients with de
novo coronary lesions showed an excellent anti-
restenotic effect on the 9-month angiography. Currently,
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in patients with de novo coronary lesions in the
BIOFLOW-II study (Clinical Trial.gov: NCT01356888).
Results are expected in 2013. Up to now there are no
data available about the safety and efficacy of these
newly developed DES with bioresorbable polymers in
patients with TCO.
The PRISON IV trial is a prospective, randomized, sin-
gle-blinded, multicenter trial, designed to evaluate the
safety, efficacy, and angiographic outcome of hybrid
sirolimus-eluting stents with bioresorbable polymers
(Orsiro; Biotronik) compared with EES with durable
polymers (Xience Prime/Xpedition; Abbott Vascular) in
patients with successfully recanalized TCOs.
Methods/Design
Recruitment, enrolment and randomization
In this study, a total of 330 patients are equally rando-
mized for the treatment of TCOs with either a
hybrid sirolimus-eluting stent (Orsiro; Biotronik) or
an everolimus-eluting stent (Xience Prime/Xpedition;
Abbott Vascular). The process of patient recruitment,Figure 1 Study design.enrolment and randomization is summarized in Figure 1.
In detail, all patients presenting with stable coronary ar-
tery disease or acute coronary syndromes and the pres-
ence of TCOs on coronary angiography are assessed for
study eligibility in eight high-volume PCI hospitals in
the Netherlands and Belgium. Patients are eligible for
study participation if the following criteria are met: the
estimated duration of the TCO is ≥4 weeks; and there is
evidence of myocardial ischemia in the supply area of
the occluded artery. Evidence of myocardial ischemia
should be demonstrated by either nuclear imaging,
stress/perfusion magnetic resonance imaging or an
exercise test (a positive exercise test is defined as elec-
trocardiographic ST-depression ≥1.0 mm horizontal;
downsloping or upsloping ST-depression ≥2.0 mm). Fur-
thermore, the reference diameter of the target vessel
should be between 2.25 and 4.0 mm, the lesion must
successfully be crossed by a guide wire in the true distal
lumen, and successful stent deployment should be
assumable.
Patients are excluded if they are younger than 18
years, pregnant or nursing; if they are presented with
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grafts; if they are known to have an allergy for the used
anticoagulant or antiplatelet medication (clopidogrel,
prasugrel, ticagrelor, acetylsalicylic acid and heparin) or
the anti-proliferative agents (sirolimus and everolimus)
mounted on the stents; or if life expectancy is less than
1 year or contributing factors make long-term follow-up
not possible.
The randomization procedure is initiated after suc-
cessful wire passage of the lesion. Randomization is per-
formed using an interactive Web-based randomization
system. After entering the patient’s sex, date of birth,
randomization date and confirmation of eligibility, the
randomization outcome is provided to the investigator/
operator on the screen. Patients and referring physicians
are blinded to the assigned treatment group. However,
the operator is informed about the assigned stent.
Study oversight
The PRISON IV study is a prospective, randomized,
multicenter clinical trial performed in six Dutch and two
Belgian high-volume PCI hospitals. The Research and
Development Department at the St. Antonius Hospital
Nieuwegein is responsible for data collection and moni-
toring. The study authors are responsible for data ana-
lysis and interpretation. An independent clinical event
adjudication committee will review all endpoints
blinded. An independent Data and Safety Monitoring
Board will review all cardiac and noncardiac adverse
events unblinded, including acute kidney injury, contrast
nephropathy and major bleeding. Serious adverse
events (fatal, life-threatening, disabling or resulting in
hospitalization or prolongation of hospitalization) are
reported to the Data and Safety Monitoring Board
within 24 hours.
The study is supported by an unrestricted grant from
Biotronik SE & Co. KG. The sponsor has no role in the
study design, data collection, analysis, interpretation of
the data, drafting of the final manuscript, or the decision
to submit the manuscript for publication. All institu-
tional review boards of the local centers approved the
study. Written informed consent is obtained prior to the
procedure. The study is performed in compliance with
the standards of Good Clinical Practice (ICH/E6/R1)
and the Declaration of Helsinki (Washington 2002). The
study is registered at Clinical Trials.gov number,
NCT01516723.
Angiographic definitions
TCO is defined as an absence of antegrade flow of con-
trast distal to the occlusion (Thrombolysis and Myocar-
dial Infarction flow 0 according to the Thrombolysis and
Myocardial Infarction Grade flow) and only minimal
flow of contrast distal to the occluded vessel(Thrombolysis and Myocardial Infarction Grade flow I)
[22]. The duration of the coronary occlusion is at least 4
weeks and is estimated by clinical information. Chronic
total occlusion is defined as a TCO with duration >3
months according to the guidelines on myocardial revas-
cularization of the European Society of Cardiology [23].
The estimated length of the occlusion was measured
from the proximal point of the total occlusion to the
most distal point of the lesion, which was visualized with
the first contrast injection after successful recanalization.
The coronary segment is defined as the stented segment
including the margins 5 mm distal and proximal to the
stents.
Angioplasty procedure
The procedure is performed by either the radial or fem-
oral approach with standard coronary catheterization
techniques. The major goal is to achieve residual diam-
eter stenosis <30% after stent implantation on visual as-
sessment. Prior to the procedure, patients receive 5,000
to 10,000 international units heparin, followed by a
bolus of 5,000 international units every additional hour
of the procedure. Patients are equally assigned to the hy-
brid sirolimus-eluting stent or the everolimus-eluting
stent. In the case of additional stents, only the assigned
stent type is used per lesion and/or vessel. Post-stent
dilatation is performed with high inflation pressures in
all patients. All patients receive dual anti-platelet therapy
for at least 12 months. Patients are preloaded with 300
mg aspirin and 300 to 600 mg clopidogrel at least 1 day
before the procedure. Aspirin is continued at a once-
daily dose of 80 to 100 mg lifelong and clopidogrel 75
mg once daily for at least 12 months. Operators are
advised to follow the European Society of Cardiology
guidelines on acute coronary syndromes concerning dual
anti-platelet therapy, if patients are already treated with
another PY12 inhibitor (ticagrelor 2× 90 mg or prasugrel
1×10 mg/1×5 mg; age >75 years or weight <60 kg) for a
prior coronary event [24,25].
Quantitative coronary analysis
Coronary angiograms are digitally recorded at baseline,
immediately after the procedure, and at 9-month follow-
up, and are assessed offline by an independent angio-
graphic core laboratory (St Antonius Hospital Angio-
graphic Core Laboratory, Nieuwegein, the Netherlands)
with an automatic edge-detection system (CMS version
5.3; Medis Medical Imaging Systems, Leiden, the
Netherlands) by experienced personnel who are blinded
for clinical information and type of stent implanted. Be-
fore angiography, 100 to 300 μg nitroglycerin is adminis-
tered intracoronary. The nontapered tip of the catheter
is used as the calibration standard. All lesions are
assessed in at least two orthogonal views; the projection
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quantitative coronary angiography analysis, and views
with the least foreshortening are used for measuring the
length of the occlusion. In disease-free proximal seg-
ments, the reference diameter is measured. Cineangio-
grams are obtained before, immediately after, and at 9
months using the same views at all times. Any coronary
angiography performed within 6 months after the initial
procedure is considered unscheduled. When an un-
scheduled angiography will be followed by target lesion
or target vessel revascularization (TLR/TVR; either PCI
or coronary artery bypass grafting), no further angio-
gram is needed. However, if no revascularization is per-
formed at the repeated angiography, the scheduled 9-
month angiography is still required. If the angiography
takes place after 6 months, the 9-month angiography is
omitted. Quantitative measurement will include the
reference diameter of the vessel and the minimal lumen
diameter. Of those measurements the following derived
parameters are calculated: acute recoil, percentage of
diameter stenosis, acute gain, late luminal loss, net lu-
minal gain, and late loss index (late loss divided by the
acute gain). Quantitative coronary analysis is used to
evaluate the stented area (in-stent) and the area that
included the stented segment as well as the 5-mm mar-
gins proximal and distal to the stent (in-segment).
Angiographic binary in-stent restenosis is defined as
≥50% residual diameter stenosis within the stent. In-
segment binary restenosis is defined as ≥50% residual
diameter stenosis located in the stent and/or at the 5-
mm proximal or 5-mm distal edge. Reocclusion is
defined as a recurrent total occlusion at the previous
angioplasty site.
Optical coherence tomography analysis
Optical coherence tomography (OCT) images are
obtained in a total of 60 patients equally divided be-
tween the two stent groups during the follow-up angio-
gram at 9 months. The OCT procedures are performed
in the first 60 patients treated in St. Antonius Hospital
or UZ Leuven Hospital. All images are obtained with an
optical frequency domain imaging system (C7XR OCT
Imaging System; St Jude Medical, St Paul, MN, USA)
and stored for offline analysis by an independent core la-
boratory at Leuven University Hospital (UZ Leuven Hos-
pital, Medical Imaging Centre, Leuven, Belgium). Images
are acquired with an automated pullback at a rate of 20
mm/second. Prior to the pullback, a bolus of 100 to 300
μg nitroglycerine is administered. The lens on the OCT
wire is placed approximately 5 mm distal to the distal
edge of the implanted stent and the pullback should in-
clude at least 5 mm of vessel proximal to the stent. All
cross-sectional images (frames) are screened for quality
assessment. Frames are excluded from analysis if anyportion of the vessel is out of screen, if a side branch oc-
cupies >45° of the cross-section or if the image has poor
quality caused by residual blood, sew-up artifacts, or re-
verberation. A dedicated automated software system
developed at the Leuven Medical Imaging Centre (Odi-
erna) is used for quantitative OCT analysis [26]. The fol-
lowing parameters are measured and/or calculated:
percentage of malapposed stent struts; percentage of
uncovered stent struts; tissue strut thickness (μm);
neointimal hyperplasia; and absolute and percentage vol-
ume of intimal hyperplasia (mm3). Quantitative strut
level analysis is performed every third frame (0.6 mm
interval) along the entire target segment. The algorithm
automatically determines the center of the luminal sur-
face of the strut blooming and calculates its distance to
the lumen contour. Stent strut malapposition is defined
when this value is higher than the sum of strut thickness
plus abluminal polymer thickness according to the stent
manufacturer specifications plus a compensation of 20
μm to correct for strut blooming. The final cutoff value
for malapposition is 90 μm for the hybrid sirolimus-
eluting stent and 110 μm for the everolimus-eluting
stent. A total percentage of malapposed struts is
reported. If neointima is absent, a value of 0 is assigned.
From these values, the total percentage of uncovered
struts and the total volume of neointimal area are calcu-
lated. Furthermore, thickness of the neointimal coverage
for each stent strut is reported.
Long-term follow-up
Clinical follow-up is performed at 1, 6 and 12 months
and an annual evaluation up to 5 years. An independent
clinical event committee, members of which are unaware
of the patient’s treatment assignment, will review all
clinical endpoints during follow-up. Recurrent angina, a
positive exercise test, abnormal dobutamine stress mag-
netic resonance imaging and new perfusion defects on
nuclear examination are considered clinical signs of re-
stenosis. Follow-up angiography is performed earlier if
there are clinical signs of restenosis, followed by revas-
cularization when indicated. Percutaneous or surgical
revascularization are regarded clinically driven if stenosis
of the treated lesion was ≥50% of the lumen diameter on
the basis of quantitative coronary angiography in the
presence of ischemic signs or symptoms, or if there is
diameter stenosis ≥70% irrespective of the presence or
absence of ischemic signs or symptoms. Death, myocar-
dial infarction (MI; defined as the presence of new sig-
nificant Q waves or an elevation of creatine kinase or its
MB isoenzyme to at least twice the upper limit) and
clinically driven target lesion revascularization (TLR;
defined as revascularization due to a stenosis within a 5
mm border proximal or distal to the stent) are recorded
as major adverse cardiac events. Other secondary clinical
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revascularization in the entire coronary vessel proximal
and distal of the target lesion, including revasculariza-
tion in side braches), target vessel failure (TVF; a com-
posite of cardiac death, MI and clinically driven TVR)
and stent thrombosis according to the definitions of the
Academic Research Consortium. Cardiac death is
defined as any death due to immediate cardiac cause
(MI, low-output failure, fatal arrhythmia); death related
to the procedure, nonwitnessed death, and death of
unknown cause. Hypertension is defined as systolic
blood pressure >140 mmHg and/or diastolic blood pres-
sure >90 mmHg or use of antihypertensive drugs.
Diabetes mellitus is defined as fasting venous glucose
concentrations ≥7.8 mmol/l (140.5 mg/dl) or use of
glucose-lowering drugs. Hypercholesterolemia is defined as
fasting plasma cholesterol level >5.0 mmol/l (193 mg/dl)
or use of cholesterol-lowering drugs. Finally, the oc-
currences of angina will be recorded in the Canadian
Cardiovascular Society classification.
Endpoint definitions
The primary endpoint is in-segment late luminal loss at
9 months as assessed with quantitative coronary angiog-
raphy. Secondary angiographic endpoints include the
following: in-stent late luminal loss, acute recoil, acute
gain, net luminal gain, late loss index, minimal lumen
diameter, percentage of diameter stenosis, in-stent and
in-segment binary restenosis and reocclusions at 9-
month angiographic follow-up. Secondary clinical end-
points include a composite of major adverse cardiac
events (death, MI and clinically driven target lesion
revascularization), clinically driven TVR, TVF (cardiac
death, MI, clinically driven TVR) and stent thrombosis
up to 5 years of clinical follow-up. Tertiary OCT
endpoints at 9-month follow-up are the following: per-
centage of uncovered stent struts, percentage of malap-
posed stent struts, tissue strut thickness, and absolute
and percentage intimal hyperplasia. According to the
new Academic Research Consortium definitions, stent
thrombosis is defined as definitive if there is angio-
graphic documentation of either occlusion of the target
lesion or thrombus within or adjacent to a previously
stented segment. Stent thrombosis is defined as probable
if sudden unexplained death occurs within 30 days or if
target vessel MI occurs without angiographic documen-
tation, and is defined as possible if a sudden unexplained
death that could not be attributed to another cause
occurs after 30 days.
Statistical analysis
The objective of the study is to assess whether the out-
come of treatment with the hybrid sirolimus-eluting
stent is non-inferior to the outcome of treatment withthe everolimus-eluting stent in patients with TCOs. The
non-inferiority margin is set at the conventional level of
0.2 mm. The null hypothesis of inferiority of the hybrid
sirolimus-eluting stent (Orsiro; Biotronik) is rejected
when the upper limit of the 95% confidence interval for
the observed difference in late loss falls below 0.2 mm.
For the sample size calculation, we assumed that the
mean late luminal loss is equal at 0.16 mm [15] in both
treatment groups, with a common standard deviation of
0.55 mm. With 131 patients per treatment arm, the
study has 90% power to reject the null hypothesis of in-
feriority of the hybrid sirolimus-eluting stent (Orsiro;
Biotronik) relative to the everolimus-eluting stent
(Xience Prime/Xpedition; Abbott Vascular). Analyzable
follow-up angiograms are expected to be available for
approximately 80% of the patients. Therefore, 165
patients per treatment arm are included in this study.
Sample size calculations were performed with the use of
the NQUERY computer program (Statistical Solutions,
Saugus, MA, USA). The primary endpoint and other
angiographic endpoints are both analyzed per protocol
and on an intention-to-treat principle. No formal statis-
tics are performed on clinical endpoints. Analysis of
clinical endpoints is performed for descriptive purposes
only on an intention-to-treat principle. The analysis of
the OCT data is performed in an exploratory context.Conclusions
The PRISON II and PRISON III studies have shown favor-
able angiographic results for both the sirolimus-eluting
stent and the Resolute zotarolimus-eluting stent for the
treatment of TCOs. Recently, the everolimus-eluting stent
with durable polymers also showed promising results in
patients with chronic total occlusions. However, new DES
with a bioresorbable polymer coating have emerged. At
the moment, none of these stents with bioresorbable poly-
mers have been evaluated in complex lesions such as
TCO. The PRISON IV study evaluates the efficacy, safety,
and angiographic outcome of the hybrid sirolimus-eluting
stents with bioresorbable polymers compared with EES
with durable polymers in successfully recanalized TCOs.Trial status
Recruitment started in February 2012.
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